当日关注点 来自交易信息汇总：2月26日主力资金净流出2570.18万元，散户资金净流入1964.72万元。 截至2026年2月26日收盘，爱尔眼科(300015)报收于10.59元，下跌1.03%，换手率0.56%，成交量44.33万 手，成交额4.7亿元。 董秘最新回复 投资者： 新春伊始，相关部门将继续加大力度扩消费，持续挖掘投资新消费市场，作为医疗消费的龙 头公司，如何提升核心竞争力，深化管理水平，改善各地区医院末梢治理效能，大力实施科技赋能医疗 服务，切实提升消费医疗的整体服务质量，加大宣传自身眼科医疗优势，在新一轮消费刺激赢得先机， 用先进的医疗水平让消费者放心、患者满意、家人安心？ 董秘： 谢谢您对公司的关注。公司以患者为中心，持续提升医疗技术、创新服务模式，满足患者的多 层次需求，让患者满意、家人安心、社会尊重，从而不断提高品牌影响力，实现高质量的可持续成长。 投资者： 请问，公司去年年末没有发布业绩预告，近期会发布业绩快报吗。 董秘： 谢谢您对公司的关注。根据《深圳证券交易所创业板股票上市规则（2024 年修订）》6.2.2款规 定，公司无需发布业绩预告。2025年度经营正常，将于2026年 ...

Core Insights - The company reported a stable performance in the first three quarters of 2025, with revenue of 2.201 billion yuan (+2.99%) and a net profit attributable to shareholders of 16 million yuan (+3.21%) [1] - The third quarter alone saw revenue of 741 million yuan (+3.48%) and a significant increase in net profit attributable to shareholders, reaching 1.68 million yuan (+106.13%) [1] Revenue and Profit Analysis - Revenue growth has slowed due to changes in consumer demand for medical services amid a complex macroeconomic environment [2] - The company's refractive business remains a significant revenue contributor, with efforts to enhance customer spending through new surgical techniques [2] - The gross profit margin for the first three quarters was 37.12%, showing a slight decline, potentially linked to changes in product revenue structure [2] Cost Management and Profitability - The company increased its IT investment, with a research and development expense ratio of 0.37%, up by 0.14 percentage points year-on-year [2] - Management expense ratio decreased from 14.67% to 10.85%, attributed to a slowdown in the company's expansion pace [2] - The non-recurring net profit attributable to shareholders improved to 25 million yuan (+34.71%) [2] Strategic Focus - The company is shifting its strategic focus towards organic growth and operational efficiency, with a significant reduction in ongoing construction projects by 74.40% compared to the beginning of the year [3] - Investment cash outflows for fixed asset purchases decreased by 66.74%, indicating a pause in large-scale expansion [3] - The introduction of new technology, such as the VisuMax 800, aims to strengthen the company's competitive edge in the refractive sector [3] Future Outlook - The company expects new hospitals to enter a profit ramp-up phase, with projected net profits for 2025-2027 at 33 million, 126 million, and 174 million yuan respectively [3] - The estimated earnings per share (EPS) for the same period are projected to be 0.22, 0.84, and 1.16 yuan [3] - A target price of 42.05 yuan is set based on a 50 times PE valuation for 2026, maintaining a "recommended" rating [3]